Sánchez-Beato M, Piris M A, Martínez-Montero J C, García J F, Villuendas R, García F J, Orradre J L, Martínez P
Department of Pathology, Virgen de la Salud' Hospital, Toledo, Spain.
J Pathol. 1996 Sep;180(1):58-64. doi: 10.1002/(SICI)1096-9896(199609)180:1<58::AID-PATH610>3.0.CO;2-W.
Mutations in the p53 tumour suppressor gene are the most common genetic alteration found in human cancers. Most of them are accompanied by stabilization of the protein, which renders it detectable through immunohistochemical techniques. Although p53 expression is a very common finding in Hodgkin's disease (HD), the status of the p53 gene is scarcely known, due to the difficulty in sequencing this gene in a lesion in which tumour cells are thought to constitute a very minor subpopulation, diluted in a background of supposedly benign cells. The pattern of expression of two downstream p53 proteins (MDM2 and p21 WAF1/CIP1, was studied as an indirect way of assessing p53 gene status. MDM2 is a wild-p53 inducible protein which may form a complex with p53, abrogating its function, as has been found in human sarcomas and other malignancies. p21WAF1/CIP1 is another protein inducible by wild-type p53, involved in inhibiting cell-cycle progression, through binding to cyclin/cyclin-dependent-kinase complexes. MDM2 and p21WAF1/CIP1 immunostaining was detected in all the cases analysed, independently of histological type, and were mainly present in Sternberg-Reed and Hodgkin (H & SR) cells. These immunohistochemical results were confirmed by Western blotting. To study the cause of MDM2 protein accumulation, MDM2 mRNA expression was also investigated by reverse transcription polymerase chain reaction (RT-PCR). The results show the presence of MDM2 transcripts in all cases of HD, albeit at lower levels than those found in reactive lymphoid tissue. These results seem to support the hypothesis that p53 is transcriptionally active in at least some of the H & SR cells in HD, and is able to induce MDM2 and p21WAF1/CIP1 protein expression.
p53肿瘤抑制基因的突变是人类癌症中最常见的基因改变。其中大多数伴随着蛋白质的稳定,这使得它可以通过免疫组织化学技术检测到。虽然p53表达在霍奇金病(HD)中很常见,但由于在一个肿瘤细胞被认为只占非常小的亚群且稀释于假定的良性细胞背景中的病变中对该基因进行测序存在困难,p53基因的状态几乎不为人知。研究了两种p53下游蛋白(MDM2和p21WAF1/CIP1)的表达模式,作为评估p53基因状态的一种间接方法。MDM2是一种野生型p53诱导蛋白,它可能与p53形成复合物,从而废除其功能,这在人类肉瘤和其他恶性肿瘤中已被发现。p21WAF1/CIP1是另一种由野生型p53诱导的蛋白,通过与细胞周期蛋白/细胞周期蛋白依赖性激酶复合物结合参与抑制细胞周期进程。在所有分析的病例中均检测到MDM2和p21WAF1/CIP1免疫染色,与组织学类型无关,且主要存在于施特恩贝格-里德细胞和霍奇金细胞(H & SR细胞)中。这些免疫组织化学结果通过蛋白质印迹法得到证实。为了研究MDM2蛋白积累的原因,还通过逆转录聚合酶链反应(RT-PCR)研究了MDM2 mRNA的表达。结果显示在所有HD病例中均存在MDM2转录本,尽管其水平低于在反应性淋巴组织中发现的水平。这些结果似乎支持这样的假设,即p53在HD的至少一些H & SR细胞中具有转录活性,并且能够诱导MDM2和p21WAF1/CIP1蛋白表达。